Recommended Flucloxacillin Dosing for MSSA Bacteremia
For methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia, flucloxacillin should be administered at 12 g/day IV divided into 4-6 doses (typically 2 g every 4 hours or 3 g every 6 hours) for 4-6 weeks depending on complexity of infection. 1
Dosing Algorithm by Clinical Scenario
Uncomplicated MSSA Bacteremia (Native Valve)
- Dose: Flucloxacillin 12 g/day IV in 4-6 divided doses
- Duration: 4 weeks minimum 1
- Criteria for "uncomplicated": No endocarditis, no prosthetic material, blood cultures clear within 2-4 days, fever resolves within 72 hours, no metastatic foci
Complicated MSSA Bacteremia or Native Valve Endocarditis
- Dose: Flucloxacillin 12 g/day IV in 4-6 divided doses
- Duration: 4-6 weeks 1
- Do NOT add gentamicin - no clinical benefit demonstrated and increases nephrotoxicity 1
Prosthetic Valve Endocarditis
- Dose: Flucloxacillin 12 g/day IV in 4-6 doses
- Duration: ≥6 weeks 1
- Add rifampin 900-1200 mg/day (in 2-3 divided doses) starting 3-5 days after initial therapy once bacteremia cleared 1
- Add gentamicin 3 mg/kg/day IV for first 2 weeks only 1
Pediatric Dosing
- Dose: 200-300 mg/kg/day IV in 4-6 equally divided doses 1
- Maximum: Do not exceed adult doses
- Duration: Same as adults based on complexity
Critical Management Points
Source control is mandatory - remove infected intravascular devices, drain abscesses, debride infected tissue. Failure to remove infected material increases mortality and relapse rates significantly.
Follow-up blood cultures must be obtained 2-4 days after initial positive cultures to document clearance. Persistent bacteremia ≥48 hours increases 90-day mortality to 39% 2.
Echocardiography is required for all patients: Transthoracic echocardiography (TTE) at minimum; transesophageal echocardiography (TEE) is superior for detecting vegetations and should be performed in high-risk patients (persistent bacteremia, persistent fever, implantable cardiac devices, metastatic infection) 1, 2.
Important Caveats
The 2015 ESC guidelines provide Class I, Level B evidence for this dosing regimen 1. While recent data from the SNAP trial 3 demonstrates cefazolin is non-inferior to flucloxacillin with lower nephrotoxicity, flucloxacillin remains a guideline-recommended first-line agent when available.
Do not use oral step-down therapy routinely - the entire treatment course should be IV for standard bacteremia. Early oral switch (after 5-7 days) may be considered only in highly selected low-risk cases with documented blood culture clearance and clinical stability 4, 2.
Combination therapy with rifampin or gentamicin is NOT recommended for uncomplicated bacteremia or native valve endocarditis - reserve for prosthetic valve endocarditis only 1, 5.
The high daily dose (12 g/day) is necessary to achieve adequate serum bactericidal activity against S. aureus and penetration into infected tissues, particularly in endovascular infections 1, 6.